Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology

Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology

Wednesday, March 27, 2019

Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology — Statistically Significant Improvement Indicates Trofinetide’s Potential for Treating Rett Syndrome — Trofinetide for Rett Syndrome has Fast Track Status and Orphan Drug Designation in the U.S. and Orphan Drug Designation in … Read More

Dr. Steven Kaminsky Retiring, RSO Honors Chief Science Officer

Thursday, March 7, 2019

Dr. Steven Kaminsky Retiring, RSO Honors Chief Science Officer Chief Science Officer Dr. Steven Kaminsky has announced his retirement this spring. Steve has served faithfully for the last seven years advancing research toward the treatment and cure of Rett syndrome. Instrumental in connecting trofinetide – a compound developed under the Department of Defense to treat … Read More